Compounds > azacitidine

azacitidine and Hormone-Dependent Neoplasms

azacitidine has been researched along with Hormone-Dependent Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonfili, P; Di Staso, M; Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Pestell, RG; Tombolini, V; Vitturini, A1
Day, ML; Gschwend, JE; Kuefer, R; McCabe, MT; Wojno, KJ; Zorn, CS1
Dubovsky, JA; McNeel, DG1
Dekker, A; Dorssers, LC; Foekens, JA; van Agthoven, T; van Agthoven, TL1
Dahiya, R; Dharia, A; Li, LC; Nojima, D; Perinchery, G; Ribeiro-Filho, L; Yen, TS1

Other Studies

5 other study(ies) available for azacitidine and Hormone-Dependent Neoplasms

ArticleYear
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    The Prostate, 2010, Volume: 70, Issue:11

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Tosyl Compounds

2010
5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-01, Volume: 13, Issue:7

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Azacitidine; Castration; Combined Modality Therapy; Decitabine; Disease Models, Animal; Male; Mice; Mice, Transgenic; Neoplasms, Hormone-Dependent; Prostatic Neoplasms

2007
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
    The Prostate, 2007, Dec-01, Volume: 67, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Specificity; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunoglobulin G; Male; Membrane Proteins; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2007
Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
    Molecular endocrinology (Baltimore, Md.), 1994, Volume: 8, Issue:11

    Topics: Azacitidine; Breast Neoplasms; Down-Regulation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Keratins; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptor, ErbB-2; Receptors, Estradiol; Receptors, Progesterone; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

1994
CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
    Cancer, 2001, Oct-15, Volume: 92, Issue:8

    Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Estrogen Receptor beta; Gene Expression Regulation; Humans; Male; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2001